In October of this year, the New Drug Research Center and the Anpaku Center, both group companies, were merged. As a result, it is now possible for a single company to conduct all processes from non-clinical to clinical trials, which is rare in Japan. We are now able to seamlessly propose non-clinical safety and efficacy studies and clinical studies (food and pharmaceuticals), which have been the strong points of each company.